Sigyn Therapeutics, Inc.
SIGY· OTC
SIGYSigyn Therapeutics, Inc.
Filed Nov 14, 2025 · 10-Q · 45 days after period end · 0001493152-25-023387
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Net Income | -$578.50K | -$1.20M | -$905.73K | -$726.51K |
| EPS Diluted | -$0.36 | -$0.94 | -$0.82 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end
